Amarin Corp plc (ADR) (NASDAQ:AMRN)
CAPS Rating:
The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.
The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.
Recs
Great product with Vascepa. High likelihood for acquisition by a bigger pharma (maybe AZN). Huge market potential.